118 related articles for article (PubMed ID: 23831764)
1. Anti-androgen effects of the pyrethroid pesticide cypermethrin on interactions of androgen receptor with corepressors.
Pan C; Wang Q; Liu YP; Xu LF; Li YF; Hu JX; Jiang M; Zhang JP; Zhang MR; Yu HM; Zhou JL; Zhou XL; Xu LC
Toxicology; 2013 Sep; 311(3):178-83. PubMed ID: 23831764
[TBL] [Abstract][Full Text] [Related]
2. Effects of cypermethrin on the ligand-independent interaction between androgen receptor and steroid receptor coactivator-1.
Pan C; Liu YP; Li YF; Hu JX; Zhang JP; Wang HM; Li J; Xu LC
Toxicology; 2012 Sep; 299(2-3):160-4. PubMed ID: 22664485
[TBL] [Abstract][Full Text] [Related]
3. Anti-androgen effects of cypermethrin on the amino- and carboxyl-terminal interaction of the androgen receptor.
Hu JX; Li YF; Pan C; Zhang JP; Wang HM; Li J; Xu LC
Toxicology; 2012 Feb; 292(2-3):99-104. PubMed ID: 22172556
[TBL] [Abstract][Full Text] [Related]
4. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
5. Inhibition effect of cypermethrin mediated by co-regulators SRC-1 and SMRT in interleukin-6-induced androgen receptor activation.
Wang Q; Zhou JL; Wang H; Ju Q; Ding Z; Zhou XL; Ge X; Shi QM; Pan C; Zhang JP; Zhang MR; Yu HM; Xu LC
Chemosphere; 2016 Sep; 158():24-9. PubMed ID: 27239967
[TBL] [Abstract][Full Text] [Related]
6. Anti-androgenic mechanisms of Bisphenol A involve androgen receptor signaling pathway.
Wang H; Ding Z; Shi QM; Ge X; Wang HX; Li MX; Chen G; Wang Q; Ju Q; Zhang JP; Zhang MR; Xu LC
Toxicology; 2017 Jul; 387():10-16. PubMed ID: 28645579
[TBL] [Abstract][Full Text] [Related]
7. [Androgen receptor and SMRT].
Liao GQ; Tang HH; Lü XS
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 29(2):157-62. PubMed ID: 16145900
[TBL] [Abstract][Full Text] [Related]
8. The androgen receptor recruits nuclear receptor CoRepressor (N-CoR) in the presence of mifepristone via its N and C termini revealing a novel molecular mechanism for androgen receptor antagonists.
Hodgson MC; Astapova I; Cheng S; Lee LJ; Verhoeven MC; Choi E; Balk SP; Hollenberg AN
J Biol Chem; 2005 Feb; 280(8):6511-9. PubMed ID: 15598662
[TBL] [Abstract][Full Text] [Related]
9. Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression.
Godoy AS; Sotomayor PC; Villagran M; Yacoub R; Montecinos VP; McNerney EM; Moser M; Foster BA; Onate SA
Biochem Biophys Res Commun; 2012 Jul; 423(3):564-70. PubMed ID: 22695118
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
11. The corepressors silencing mediator of retinoid and thyroid hormone receptor and nuclear receptor corepressor are involved in agonist- and antagonist-regulated transcription by androgen receptor.
Yoon HG; Wong J
Mol Endocrinol; 2006 May; 20(5):1048-60. PubMed ID: 16373395
[TBL] [Abstract][Full Text] [Related]
12. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor.
Cheng S; Brzostek S; Lee SR; Hollenberg AN; Balk SP
Mol Endocrinol; 2002 Jul; 16(7):1492-501. PubMed ID: 12089345
[TBL] [Abstract][Full Text] [Related]
14. Inability of NCoR/SMRT to repress androgen receptor transcriptional activity in prostate cancer cell lines.
Laschak M; Bechtel M; Spindler KD; Hessenauer A
Int J Mol Med; 2011 Oct; 28(4):645-51. PubMed ID: 21720703
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor.
Hodgson MC; Shen HC; Hollenberg AN; Balk SP
Mol Cancer Ther; 2008 Oct; 7(10):3187-94. PubMed ID: 18852122
[TBL] [Abstract][Full Text] [Related]
16. The amino terminus of the human AR is target for corepressor action and antihormone agonism.
Dotzlaw H; Moehren U; Mink S; Cato AC; Iñiguez Lluhí JA; Baniahmad A
Mol Endocrinol; 2002 Apr; 16(4):661-73. PubMed ID: 11923464
[TBL] [Abstract][Full Text] [Related]
17. Agonist-antagonist induced coactivator and corepressor interplay on the human androgen receptor.
Dotzlaw H; Papaioannou M; Moehren U; Claessens F; Baniahmad A
Mol Cell Endocrinol; 2003 Dec; 213(1):79-85. PubMed ID: 15062576
[TBL] [Abstract][Full Text] [Related]
18. Nuclear corepressor and silencing mediator of retinoic and thyroid hormone receptors corepressor expression is incompatible with T(3)-dependent TRH regulation.
Becker N; Seugnet I; Guissouma H; Dupre SM; Demeneix BA
Endocrinology; 2001 Dec; 142(12):5321-31. PubMed ID: 11713232
[TBL] [Abstract][Full Text] [Related]
19. Determination of nuclear receptor corepressor interactions with the thyroid hormone receptor.
Makowski A; Brzostek S; Cohen RN; Hollenberg AN
Mol Endocrinol; 2003 Feb; 17(2):273-86. PubMed ID: 12554754
[TBL] [Abstract][Full Text] [Related]
20. Interaction of silencing mediator for retinoid and thyroid receptors with steroid and xenobiotic receptor on multidrug resistance 1 promoter.
Hirooka-Masui K; Lesmana R; Iwasaki T; Xu M; Hayasaka K; Haraguchi M; Takeshita A; Shimokawa N; Yamamoto K; Koibuchi N
Life Sci; 2013 May; 92(17-19):911-5. PubMed ID: 23562850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
